5-Fluorouracil (5-FU) + Cis-diamminedichloroplatinum (DDP) Treatment of Human Colorectal Tumor Xenografts

1988 ◽  
pp. 140-140
Author(s):  
G. Pratesi ◽  
M. Tortoreto ◽  
G. Parmiani
Keyword(s):  
Colorectal Tumor ◽  
Tumor Xenografts

Chemotherapeutic Sensitivity of Human Colorectal Tumor Xenografts

Oncology ◽  
1980 ◽  
Vol 37 (1) ◽  
pp. 42-50 ◽  
Author(s):  
L. Kopper ◽  
K. Lapis ◽  
Cs. Hegedüs
Keyword(s):  
Colorectal Tumor ◽  
Tumor Xenografts ◽  
Chemotherapeutic Sensitivity

Potentiation of the Antitumor Action of 5-Fluorouracil with 5-Ethyl-2′-Deoxyuridine in Human Colorectal Tumor Xenografts

Oncology ◽  
1984 ◽  
Vol 41 (3) ◽  
pp. 155-158 ◽  
Author(s):  
L. Kopper ◽  
E. Magyarosy ◽  
A. Jeney ◽  
K. Lapis ◽  
A. Szabolcs ◽  
...  
Keyword(s):  
Colorectal Tumor ◽  
Antitumor Action ◽  
Tumor Xenografts

scholarly journals Molecular Targeting of Carbonic Anhydrase IX in Mice with Hypoxic HT29 Colorectal Tumor Xenografts

PLoS ONE ◽  
2010 ◽  
Vol 5 (5) ◽  
pp. e10857 ◽  
Author(s):  
Sean Carlin ◽  
Nahida Khan ◽  
Thomas Ku ◽  
Valerie A. Longo ◽  
Steve M. Larson ◽  
...  
Keyword(s):  
Carbonic Anhydrase ◽  
Colorectal Tumor ◽  
Carbonic Anhydrase Ix ◽  
Molecular Targeting ◽  
Tumor Xenografts

Growth of Human Colorectal Tumor Xenografts in Immunosuppressed Mice Reconstituted with Normal Cells

Pathobiology ◽  
1981 ◽  
Vol 49 (3) ◽  
pp. 141-147
Author(s):  
L. Kopper ◽  
Tran van Hanh ◽  
C. Hegedüs ◽  
K. Lapis
Keyword(s):  
Colorectal Tumor ◽  
Normal Cells ◽  
Tumor Xenografts ◽  
Immunosuppressed Mice

scholarly journals Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts

2015 ◽  
Vol 13 (1) ◽  
Author(s):  
Woan-Ruoh Lee ◽  
Shing-Chuan Shen ◽  
Yi-Hsien Shih ◽  
Chia-Lun Chou ◽  
Jonathan Te-Peng Tseng ◽  
...  
Keyword(s):  
Colorectal Tumor ◽  
Tumor Xenografts

rNAPc2, a Novel Inhibitor of Tissue Factor/Factor VIIa Complex, Inhibits Tumor Growth and Metastasis in Mouse Models of Colorectal Cancer.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 923-923
Author(s):  
Jingsong Zhao ◽  
Gerard Aguilar ◽  
Michael Imperiale ◽  
Walter Funk ◽  
Arie Abo
Keyword(s):  
Colorectal Cancer ◽  
Tumor Growth ◽  
Tissue Factor ◽  
Nude Mice ◽  
Factor Viia ◽  
Colorectal Tumor ◽  
Disease Stage ◽  
Major Hemorrhage ◽  
Tumor Xenografts ◽  
Tumor Growth And Metastasis

Abstract Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel anti-metastatic, anti-angiogenic, and anti-thrombotic activities. TF is highly expressed in human colorectal tumors and the level of TF expression positively correlates with disease stage and inversely correlates with survival. To explore the therapeutic potential of rNAPc2 during tumor growth and metastasis, we tested rNAPc2 efficacy in experimental colorectal cancers in mice. Administration of rNAPc2 inhibited pulmonary metastasis in mice systemically disseminated with CT26 murine colon carcinoma cells in a dose-dependent fashion, as measured by either number of lung surface metastases or lung mass. While rNAPc2 treatment alone moderately reduced primary tumor growth, combining rNAPc2 with the cytotoxic agent 5-fluorouracil (5-FU) resulted in synergistic growth inhibition of HCT116 human colorectal tumor xenografts in nude mice. Likewise, rNAPc2 further reduced tumor growth in HCT116 human colorectal tumor xenograft-bearing mice receiving bevacizumab (humanized anti-vascular endothelial growth factor monoclonal antibody). Using CD31 and Ki67 immunohistochemisty, we found that rNAPc2 synergized with either 5-FU or bevacizumab in inhibiting microvessel density and tumor cell proliferation in HCT116 human colorectal tumor xenografts. Furthermore, rNAPc2 synergized with CPT-11 in inhibiting hepatic metastasis in nude mice with portal vein injection of HCT116 human colorectal tumor cells. Long-term administration of rNAPc2 also significantly suppressed formation of intestinal adenomas and adenocarcinomas in ApcMin/+ mice. The dosing regimens of rNAPc2 used in these studies were well tolerated up to a three-month period by recipient mice without major hemorrhage or other adverse effects. In conclusion, the synergistic tumor inhibitory activity of rNAPc2 in pre-clinical colorectal cancer models suggests that rNAPc2 may be an effective anti-tumor agent in human colorectal cancer patients to potentiate chemo- or anti-angiogenic therapies.

Sign in / Sign up

Export Citation Format

Share Document